Moderna Therapeutics just filed for what would be the biggest biotech IPO in U.S. history.
Moderna, which would list as MRNA under the NASDAQ, is looking to raise a staggering $500 million in a public offering. The biotech unicorn has already built a mammoth early valuation of more than $7 billion in private money despite having no products on the market or much in the way of clinical data to back up its hype.
The latter fact has earned the company sustained criticism from outlets such as STAT News .
Moderna's IPO offering would be facilitated by Morgan Stanley , Goldman Sachs , and...Read more ...

Moderna Therapeutics just filed for what would be the biggest biotech IPO in U.S. history.
Moderna, which would list as MRNA under the NASDAQ, is looking to raise a staggering $500 million in a public offering. The biotech unicorn has already built a mammoth early valuation of more than $7 billion in private money despite having no products on the market or much in the way of clinical data to back up its hype.
The latter fact has earned the company sustained criticism from outlets such as STAT News .
Moderna's IPO offering would be facilitated by Morgan Stanley , Goldman Sachs , and...Read more ...

The president of the company headed for the biggest IPO in biotech history has a surprisingly large pay package

Moderna Therapeutics, a buzzy startup with a $7 billion private valuation , filed paperwork on Friday to go public.
According to a regulatory filing, Moderna President Dr. Stephen Hoge has a compensation package worth almost $24 million, rivaling the paychecks of some of big pharma's most high profile CEOs.
One of the most highest-valued private companies in biotech is finally going public.
Moderna Therapeutics, a company developing treatments based on messenger RNA, has racked up a private valuation of $7 billion. On Friday, it filed with the Securities and Exchange Commission to go...Read more ...